Industry News
The latest pharmaceutical and supplement industry news — regulation updates, safety alerts, market trends, and research breakthroughs.
FDA PreCheck Program Aims to Boost Domestic Drug Manufacturing
FDA's new PreCheck Pilot Program offers increased regulatory predictability for US pharmaceutical manufacturers, marking a strategic shift toward strengthening domestic production capacity.
FDA Demands Drug Developers Post Missing Clinical Trial Data
FDA enforcement action targets widespread non-compliance with ClinicalTrials.gov reporting requirements, addressing years of transparency gaps in pharmaceutical research data.
Eli Lilly Acquires CrossBridge Bio for $300M in ADC Expansion
Lilly's $300M acquisition of CrossBridge Bio underscores Big Pharma's strategic push into antibody-drug conjugates as oncology M&A activity intensifies.
Novo Nordisk and OpenAI Forge Landmark AI Manufacturing Partnership
Novo Nordisk partners with OpenAI to deploy AI across research, manufacturing, and operations—marking a shift from discovery-only AI applications to full operational integration.
AI Drug Interaction Tools Show Wide Accuracy Gap: 52.5% to 89%
New research reveals dramatic accuracy variations in AI-powered drug interaction checkers, raising critical questions about clinical reliability as healthcare providers adopt AI tools.
FDA Approves First Generic Dapagliflozin for Heart Failure Treatment
Generic versions of FARXIGA now available as branded dapagliflozin loses exclusivity, marking a pivotal shift in affordable heart failure and diabetes treatment access.
Novo Nordisk Commits $4.1B to US Manufacturing Amid GLP-1 Surge
Danish pharma giant's massive investment addresses critical supply shortages of obesity medications and signals strategic shift toward domestic production.
Medicare Drug Price Negotiations Yield 79% Savings on First 10 Drugs
CMS announces historic negotiated prices for initial Medicare drugs under Inflation Reduction Act, with reductions up to 79% reshaping pharmaceutical pricing landscape.
Europe Loses Pharma Market Share Amid US-China Competition
European pharmaceutical dominance wanes as aggressive US trade policies and China's biotech expansion reshape global drug manufacturing and R&D investment patterns.
Gut Health Supplement Market Set to Hit $29.1B by 2033
Market analysts project the gut health supplement sector will reach $29.1 billion by 2033, driven by preventive healthcare trends and microbiome innovation.
US Pharma Tariffs Hit 100% as Manufacturing, Pricing Deals Offer Exemptions
New US tariff policy imposes up to 100% duties on pharmaceutical imports while offering exemptions for domestic manufacturing commitments and pricing agreements.
FDA Alert Signals New Era in Supplement Contamination Monitoring
FDA safety warning on Burn Slim slimming capsules reveals undeclared pharmaceutical ingredients, prompting regulatory shift in weight-loss supplement oversight.
Good Brain Tonic Recalled Over Botulism Risk in Rare Safety Alert
FDA issues urgent recall for Good Brain Tonic supplement due to potential botulism contamination, highlighting critical gaps in dietary supplement manufacturing safety.
Pentagon Leadership Shift Raises Questions for Defense Pharma Sector
Defense Secretary's removal of Army Chief creates uncertainty for pharmaceutical companies holding military contracts, particularly in biodefense and soldier health programs.
FDA Identifies Dangerous Stimulants in Gas Station Supplements
FDA warns consumers about DMAA and DMHA in widely available supplements sold at gas stations, citing serious cardiovascular risks including heart attacks.
AI-Discovered Drugs Double Phase I Success Rates to 80-90%
AI-developed pharmaceutical candidates are achieving 80-90% Phase I trial success rates, nearly doubling the industry standard and validating AI's transformative impact.
Neurocrine Acquires Soleno for $2.9B in Rare Disease Play
Neurocrine Biosciences expands beyond neuroscience with $2.9B Soleno acquisition, marking strategic entry into rare obesity disorder treatments.
Macleods Recalls 1,300+ Bottles of Levothyroxine for Subpotency
Macleods Pharmaceuticals initiates voluntary recall of Levothyroxine Sodium tablets due to subpotency concerns, affecting patients dependent on precise thyroid hormone replacement.
Lilly Acquires Centessa to Advance Novel Sleep Disorder Treatments
Eli Lilly's acquisition of Centessa Pharmaceuticals signals major expansion into sleep disorders through innovative orexin receptor 2 agonist therapies for excessive daytime sleepiness.
FDA Issues Urgent Warning: Addall XR Products Contaminated
FDA warns consumers against using Addall XR Shot and XL capsules from ZMB Enterprises due to contamination concerns. Retailers urged to remove products immediately.